Joshi, Sunil K.
Davare, Monika A.
Druker, Brian J.
Tognon, Cristina E.
Article History
Received: 11 June 2019
Accepted: 18 June 2019
First Online: 24 September 2019
Compliance with ethical standards
:
: BJD potential competing interests— SAB: Aileron Therapeutics, ALLCRON, Cepheid, Vivid Biosciences, Celgene, RUNX1 Research Program, EnLiven Therapeutics, Gilead Sciences (inactive), Baxalta (inactive), Monojul (inactive); SAB & Stock: Aptose Biosciences, Blueprint Medicines, Beta Cat, Third Coast Therapeutics, GRAIL (inactive), CTI BioPharma (inactive); Scientific Founder: MolecularMD (inactive, acquired by ICON); Board of Directors & Stock: Amgen; Board of Directors: Burroughs Wellcome Fund, CureOne; Joint Steering Committee: Beat AML LLS; Founder: VP Therapeutics; Clinical Trial Funding: Novartis, Bristol-Myers Squibb, Pfizer; Royalties from Patent 6958335 (Novartis exclusive license) and OHSU and Dana-Farber Cancer Institute (one Merck exclusive license). SKJ declares no potential competing interests. MAD and CET potential competing interests—Research funding from Ignyta (inactive).